B-Cell Non-Hodgkin Lymphoma Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working

Non-lymphoma Hodgkin's is cancer that starts in the lymphatic system, which is part of the body's immune system. White blood cells called lymphocytes proliferate improperly in non-lymphoma Hodgkin's and can form tumors throughout the body.

Non-lymphoma Hodgkin's is a type of lymphoma that is not Hodgkin's lymphoma. This category encompasses a wide range of subcategories. The most prevalent subtypes are diffuse large B-cell lymphoma and follicular lymphoma. Hodgkin's lymphoma is the other major type of lymphoma. 

DelveInsight’s “B-Cell Non-Hodgkin Lymphoma – Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the B-Cell Non-Hodgkin Lymphoma, historical and forecasted epidemiology as well as the B-Cell Non-Hodgkin Lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 Some of the key facts of the B-Cell Non-Hodgkin Lymphoma Market Report: 

  • Non-lymphoma Hodgkin's can strike at any age, but it is more common as people get older. It is more common in adults aged 60 and above

  • In India, B-cell NHL accounts for 80-85% of all NHLs [10, 1314]. The most common subtype of NHL is diffuse large B-cell NHL (60 percent), followed by indolent lymphoma (12-20 percent). T-cell lymphomas make for 10-15% of all cases.

  • Non-Hodgins' lymphoma (NHL) is the most prevalent hematological disease, accounting for roughly 3% of all cancer diagnoses and deaths worldwide.

  • NHL accounts for almost 4% of cancer diagnoses in the United States, with a 168 percent rise in incidence since 1975.

To request a sample of the report: https://www.delveinsight.com/sample-request/b-cell-non-hodgkin-lymphoma-marke

B-Cell Non-Hodgkin Lymphoma Symptoms:

Symptoms of the Non-Hodgkin Lymphoma are-

  • Swollen Lymph nodes can be seen in the Neck, Groin, and armpits area

  • Pain or Swelling in the Abdominal Area

  • Body Fatigue

  • Abrupt Weight loss

  • Sweating in the night 

B-Cell Non-Hodgkin Lymphoma Market 

The dynamics of the B-Cell Non-Hodgkin Lymphoma market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as and others during the forecasted period 2022-2032.

Due to the high prevalence of the Non-Hodgkin Lymphoma, the ongoing market trends are mainly focused on launches of advanced products. Some Key Players in the market are- Genmab

Hoffmann-La Roche, BioInvent International AB, CARsgen Therapeutics Co., Ltd.

 Learn more by requesting for sample @ B-Cell Non-Hodgkin Lymphoma Market Landscape  

B-Cell Non-Hodgkin Lymphoma Pipeline Therapies: 

  • GEN3009

  • Epcoritamab

  • Mosunetuzumab (IV)

  • Polatuzumab Vedotin

  • BI1206

  • Epcoritamab 

B-Cell Non-Hodgkin Lymphoma and Key Companies:

  • Genmab

  • Hoffmann-La Roche

  • BioInvent International AB

  • CARsgen Therapeutics Co., Ltd.

  • The First Affiliated Hospital of Soochow University

  • Peking University

  • Beijing Cancer Hospital

Click here to read more about B-Cell Non-Hodgkin Lymphoma Market Outlook 2032 

Related Reports:

 B-Cell Non-Hodgkin Lymphoma Pipeline  

"B-Cell Non-Hodgkin Lymphoma Pipeline Insight, 2022" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the B-Cell Non-Hodgkin Lymphoma market. A detailed picture of the B-Cell Non-Hodgkin Lymphoma pipeline landscape is provided, which includes the disease overview and B-Cell Non-Hodgkin Lymphoma treatment guidelines. 

B-Cell Non-Hodgkin Lymphoma Epidemiology 

DelveInsight's 'B-Cell Non-Hodgkin Lymphoma  Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted B-Cell Non-Hodgkin Lymphoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports by DelveInsight

Basal Cell Carcinoma Market

Birch Allergy Market

Bile Duct Neoplasm Market

Gingivitis Market

LAG 3: A Promising Next Generation Cancer Immunotherapy

Comments

Post a Comment

Popular posts from this blog

Raising the Bar: ADCs and Lung Cancer Treatment Breakthroughs

Image
  The ENHERTU Effect: A Closer Look at the Dynamic Duo Daiichi Sankyo and AstraZeneca Taking on HER2-mutant NSCLC Lung cancer remains one of the most challenging and prevalent forms of cancer. Within this landscape, innovative treatments are offering new hope. One such breakthrough is the collaboration between Daiichi Sankyo and AstraZeneca, which brings forth ENHERTU, an Antibody-Drug Conjugate (ADC). ENHERTU is making strides in targeting HER2-mutant Non-Small Cell Lung Cancer (NSCLC), a rare and challenging subset of the disease. The ENHERTU partnership aims to address this unmet medical need with a highly targeted approach. Dato-DXd vs. TRODELVY: The Battle of ADC Targeting TROP2 As the world of ADCs expands, another remarkable battle is brewing between Daiichi Sankyo's Dato-DXd and TRODELVY in their quest to target TROP2. TROP2, also known as CEACAM5, is an antigen overexpressed in various cancers, including endometrial cancer. Both ADCs hold the potential to transform the
Read more
Image
Covering the Therapeutic Advancements in Obstructive Sleep Apnea Treatment Scenario Obstructive Sleep Apnea (OSA) is a common chronic sleep disorder, which is characterized by periodic narrowing and obstruction of the pharyngeal airway during sleep, leading to a complete or partial obstruction of the airway, results of which are apneas, hypopneas, or sometimes both. Obstructive sleep apnea is a chronic and permanent condition, through proper therapy and medications the condition can be cured. Almost every system in the body is affected by Obstructive Sleep Apnea, resulting in an increased incidence of hypertension, stroke, altered immune system, and cardiovascular disease.  Obstructive Sleep Apnea is caused when the throat muscles relax during sleep, which causes the tissue in the back of the throat to collapse and block the upper airway. Daytime sleepiness is one of the most common symptoms of Obstructive Sleep Apnea. People affected with Obstructive Apnea also complain of memory pro
Read more

Market Drivers and Barriers for Vascular Stents: An In-Depth Analysis

Image
  What are Vascular Stents? Vascular stents are medical devices that are used to treat narrow or blocked blood vessels. They are small, mesh-like tubes that are inserted into the affected artery to help prop it open and improve blood flow. The global vascular stents market is expected to grow significantly in the coming years due to an increase in the prevalence of cardiovascular diseases, technological advancements in stent design, and the growing aging population. Vascular Stents Market Size and Forecast The global vascular stents market size is expected to reach USD 16.52 billion by 2028, growing at a CAGR of 6.7% from 2021 to 2028. North America dominates the market due to a high prevalence of cardiovascular diseases, increased healthcare spending, and better healthcare infrastructure. Vascular Stents Market Trends and Analysis The market is experiencing a shift towards the development of bioresorbable stents that dissolve within the body after the artery has healed. This reduces
Read more